VTA-300

**VTA-300** is an investigational cell therapy developed by Vita Therapeutics for the treatment of multiple solid tumors and certain muscular dystrophies. It employs proprietary chimeric antigen receptor (CAR) technology combined with gene editing to target tumor cells or defective muscle cells, aiming to provide a disease-modifying effect through engineered cells derived from induced pluripotent stem cells (iPSCs). The therapy is part of Vita's pipeline utilizing both autologous and hypoimmunogenic approaches to address high unmet needs in oncology and rare genetic disorders, with preclinical data supporting progression toward clinical trials.[7][9][11][13][15]